In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Translational Neuroscience in Psychiatry: Light at the End of the Tunnel

Edited by Edited by Annals of the New York Academy of Sciences editorial staff
Translational Neuroscience in Psychiatry: Light at the End of the Tunnel

Published: May 2015

Volume 1344

Learn More

Progress in developing new and more effective treatments for psychiatric disorders, particularly depression and schizophrenia, has been stymied in part because of a lack of quantitative endpoints (biomarkers) to measure disease progression and response to therapy. Additional factors delaying the development of new drugs include a lack of mechanistic understanding of standard treatments and the complexity, and often long time course, of disease, which makes disease modeling in laboratory animals challenging. This Annals volume presents a collection of papers stemming from the conference \"Translational Neuroscience in Psychiatry: Light at the End of the Tunnel,\" presented April 8, 2014 by the Biochemical Pharmacology Discussion Group of the New York Academy of Sciences, which explored recent developments that are providing new hope for a better understanding of disease progression and tractable mechanisms for drug discovery. The papers cover a range of topics, including progress in validating the use of event-related potentials and other electrophysiological means to measure sensory deficits that are increasingly recognized as features of disease pathology; improved methods for brain imaging in patients to monitor illness progression and treatment effect; development of panels of blood biomarkers that reflect ongoing brain disease pathology; and strategies for back-translating findings in humans to animal models.